PDUFA dates and FDA Panel Review dates are very important catalysts because they are ‘make or break events’ for biotech stocks.
The goal date set by the FDA for announcing its decision on a company’s New Drug Application/ Biologics License Application/sBLA/sNDA after reviewing the applications is known as the PDUFA date.
Usually, the stocks experience a run-up going into the scheduled FDA Approval decision/FDA Panel review events. So, having prior knowledge of the key dates goes a long way toward maximizing profit or minimizing loss while investing in the volatile biotech stocks.
Listed below are large cap, mid cap and small cap stocks with pending regulatory catalysts.
Get in-depth analysis and insight on investing in the high-stakes Biotech and Pharma sectors. Check out RTT Biotech Investor and our Biotech Home Page.
ALSO READ - COVID-19 Drugs In Development Calendar which lists Companies that are in Race to find a Treatment or Vaccine for the Novel Coronavirus.
March 31, 2026 15:49 ET In this week’s video, we’ll cover major biotech moves and breakthroughs - from Novartis and Merck’s blockbuster acquisitions to the first new Hunter syndrome therapy in two decades. We’ll also look at a promising alternative to daily insulin injections and the near-term catalyst for Q3 Bio, which has been hitting new 52-week highs.
A large study looked at ancient DNA from about 16,000 people who lived over the past 10,000 years in West Eurasia, and found that natural selection has influenced human genes much more than scientists once believed. By comparing DNA from ancient remains and over 6,000 people today, researchers found...
Health officials in San Francisco have confirmed the city's first case of a type of mpox called clade I, which is predicted to cause more serious illness than the type seen in the 2022 outbreak. The infected person is an unvaccinated adult who was hospitalized but is now getting better. Officials...
The modern workforce increasingly relies on night shift schedules, especially in sectors such as healthcare, information technology, and manufacturing. While these schedules support a 24-hour global economy, they often come at a high biological cost. Thyroid disorders are among the most prevalent...
Sanofi's (SNY, SNYNF,SAN.PA) protein-based COVID-19 vaccine, Nuvaxovid (NVX-CoV2705), demonstrated a significantly better tolerability profile compared to Moderna's latest mRNA vaccine, mNEXSPIKE (mRNA-1283), in the first head-to-head, double-blind, randomized phase 4 study conducted in adults. The...